Publications by authors named "C-K Liam"
Transl Lung Cancer Res
July 2024
Article Synopsis
- This study examined the effectiveness and safety of lower doses of osimertinib (20 mg and 40 mg daily) for patients with advanced NSCLC who had previously failed other treatments, compared to the standard 80 mg daily dose.
- Researchers analyzed data from 22 patients who had the EGFR T790M mutation and found that lower doses resulted in a notable overall response rate of 77.3%, with median progression-free survival of 10 months and overall survival of 13 months.
- The findings suggest that even patients with poor performance status (ECOG 3 or 4) experienced decent survival outcomes, emphasizing that lower doses of osimertinib could be a viable treatment
